Jerry Sullivan is editor of the Business Journal. He directs the paper's coverage and layout and oversees a team of award-winning reporters. He also oversees the paper's website. He can be reached at firstname.lastname@example.org.
Would-be raiders Valeant Pharmaceuticals and Bill Ackman appear to be running out of room for their argument that Allergan CEO David Pyott and his fellow board members overlook shareholders as they fight the hostile bid for the Irvine-based drug maker.
Bill Gross and big numbers go together, as our story on page 1 shows with its estimate on the value of the publicity that came with the Bond King’s jump from Pimco to Janus Capital topping $300 million.
The Insider has no dog in any fight between Bill Gross and whoever—but it now looks clear from this vantage point that a cadre of critics coordinated their condemnations of the cofounder and now ex-boss of Pimco in recent months.
Activist investor Bill Ackman has threatened to sue Allergan Inc. if the Irvine-based drug maker goes ahead with an acquisition of Salix Pharmaceuticals Ltd. in a deal that doesn’t require a vote of Allergan shareholders.
This week’s special issue puts a focus on the fastest-growing private companies based in OC, with 174 entries spread over three lists, and Irvine-based Golden State Foods the largest of the bunch at $6.6 billion in annual sales (see related stories on page 1; Special Report starting on page 21).
$5.5B Gain in 2 Years for 174 Fastest Growers Based in OC
There’s no shortage of numbers available to put some punch into this week’s coverage of the fastest-growing private companies based in Orange County.
Multiple sources tell the Insider that the Oakland Raiders have recently looked past downtown L.A. and the City of Industry to entertain the possibility of a move to the Great Park.
Gerard Widder, new GM of the Irvine Company’s Island Hotel, arrives in Newport Center with experience from several high-end Manhattan establishments, including a tenure in the same post for the flagship W.
The Dec. 18 date that’s been set for a special shareholders meeting on Valeant Pharmaceuticals’ hostile bid for Irvine-based Allergan didn’t add up to much on Wall Street, where neither company saw its shares do much last week.
Last week had some wags wondering if Allergan CEO David Pyott might be forced into an error by spending too much on an acquisition in hopes of putting the Irvine-based drug maker out of reach of hostile pursuers Valeant Pharmaceuticals and New York hedge funder Bill Ackman.